Diagnostic Center | January 29, 2024
Merck’s Keytruda reduced the risk of death by 38% for patients with RCC
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC